QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)

Compare Stocks

Date Range: 

 Elevation OncologyMiromatrix MedicalAdverum BiotechnologiesAptose BiosciencesADMA Biologics
SymbolNASDAQ:ELEVNASDAQ:MIRONASDAQ:ADVMNASDAQ:APTONASDAQ:ADMA
Price Information
Current Price$5.25$6.74$1.76$2.08$1.36
50-Day Moving Average$7.57$7.31$2.07$2.29$1.32
52-Week Low$4.25$6.45$1.69$1.96$1.01
52-Week High$16.22$16.52$14.79$7.20$3.11
MarketRank™
Overall Score2.21.72.22.32.2
Analysis Score3.53.53.03.53.6
Community Score4.85.04.14.74.9
Dividend Score0.00.00.00.00.0
Ownership Score1.70.02.53.31.7
Earnings & Valuation Score1.30.01.30.00.6
Analyst Ratings
Consensus RecommendationBuyBuyHoldBuyBuy
Consensus Price Target$20.78$22.00$6.43$11.00$5.70
% Upside from Price Target295.71% upside226.65% upside265.26% upside428.85% upside319.12% upside
Trade Information
Market Cap$121.94 million$136.42 million$172.75 million$185.01 million$266.31 million
BetaN/AN/A1.161.651.24
Average Volume54,91535,1711,979,5751,913,5574,199,785
Sales & Book Value
Annual RevenueN/AN/A$250 thousandN/A$42.22 million
Price / SalesN/AN/A690.99N/A6.31
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$6.44 per share$2.93 per share$3.53 per share$1.00 per share$0.52 per share
Price / BookN/AN/A0.50N/A2.62
Profitability
Net IncomeN/AN/A$-117.51 million$-55.24 million$-75.75 million
EPSN/AN/A($1.52)($0.63)($0.64)
Trailing P/E Ratio0.000.00N/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/A-108.60%
Return on Equity (ROE)N/AN/A-37.80%-53.69%-71.69%
Return on Assets (ROA)N/AN/A-30.35%-50.11%-32.53%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.01N/AN/A0.99
Current Ratio17.8417.5813.7311.605.41
Quick Ratio17.8417.5813.7311.601.88
Ownership Information
Institutional Ownership Percentage80.97%16.73%72.93%63.64%32.23%
Insider Ownership PercentageN/AN/A4.20%8.41%8.70%
Miscellaneous
Employees83716731407
Shares Outstanding23.23 million20.26 million98.15 million88.95 million195.81 million
Next Earnings Date2/11/2022 (Estimated)2/21/2022 (Estimated)3/7/2022 (Estimated)3/22/2022 (Estimated)3/24/2022 (Estimated)
OptionableNot OptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
ADMA Biologics Inc. (NASDAQ: ADMA) Stock Forecast For 2021: Weak With A -624.64 Percent DownsideADMA Biologics Inc. (NASDAQ: ADMA) Stock Forecast For 2021: Weak With A -624.64 Percent Downside
marketingsentinel.com - December 7 at 7:35 PM
Find Strong Cheap Stocks Under $10 to Buy in DecemberFind Strong Cheap Stocks Under $10 to Buy in December
finance.yahoo.com - December 7 at 7:35 PM
ADMA Biologics, Inc. (NASDAQ:ADMA) Receives Average Recommendation of "Buy" from AnalystsADMA Biologics, Inc. (NASDAQ:ADMA) Receives Average Recommendation of "Buy" from Analysts
americanbankingnews.com - December 3 at 11:45 AM
ADMA Biologics Inc. (ADMA) Volatility Hits 5.08% – Here Is What You Should DoADMA Biologics Inc. (ADMA) Volatility Hits 5.08% – Here Is What You Should Do
stocksregister.com - December 3 at 8:59 AM
 Brokerages Expect ADMA Biologics, Inc. (NASDAQ:ADMA) Will Announce Quarterly Sales of $21.93 Million Brokerages Expect ADMA Biologics, Inc. (NASDAQ:ADMA) Will Announce Quarterly Sales of $21.93 Million
americanbankingnews.com - December 2 at 3:46 AM
ADMA Biologics, Inc. (NASDAQ:ADMA) Expected to Announce Earnings of -$0.11 Per ShareADMA Biologics, Inc. (NASDAQ:ADMA) Expected to Announce Earnings of -$0.11 Per Share
americanbankingnews.com - November 30 at 11:20 AM
ADMA Biologics Inc. (NASDAQ: ADMA) Is Down 0.00% – Is It Capable Of A Rally?ADMA Biologics Inc. (NASDAQ: ADMA) Is Down 0.00% – Is It Capable Of A Rally?
stocksregister.com - November 30 at 10:25 AM
Is ADMA Biologics Inc. (NASDAQ: ADMA) A Good Investment For New Investors Now?Is ADMA Biologics Inc. (NASDAQ: ADMA) A Good Investment For New Investors Now?
stocksregister.com - November 26 at 9:38 AM
Future Outlook And Stock Price Performance For ADMA Biologics Inc. (NASDAQ: ADMA)Future Outlook And Stock Price Performance For ADMA Biologics Inc. (NASDAQ: ADMA)
marketingsentinel.com - November 24 at 2:27 PM
ADMA Biologics Inc.’s (NASDAQ: ADMA) Stock Forecast: Increase To $10.00 In A YearADMA Biologics Inc.’s (NASDAQ: ADMA) Stock Forecast: Increase To $10.00 In A Year
stocksregister.com - November 23 at 2:24 PM
For ADMA Biologics Inc. [ADMA], Analyst sees a rise to $5. What next?For ADMA Biologics Inc. [ADMA], Analyst sees a rise to $5. What next?
dbtnews.com - November 19 at 8:04 PM
There Is A Lot Of Upside Potential For ADMA Biologics Inc.(NASDAQ: ADMA)There Is A Lot Of Upside Potential For ADMA Biologics Inc.(NASDAQ: ADMA)
stocksregister.com - November 19 at 3:03 PM
ADMA Biologics Inc. (NASDAQ: ADMA) Thursday – Up 30.82% From The Lows, What Happens NextADMA Biologics Inc. (NASDAQ: ADMA) Thursday – Up 30.82% From The Lows, What Happens Next
marketingsentinel.com - November 19 at 10:02 AM
ADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman Elected to PPTA Source Board of DirectorsADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman Elected to PPTA Source Board of Directors
finance.yahoo.com - November 17 at 9:20 AM
Adma Biologics Advances Plasma Collection Center Expansion Plans With Opening Of New Facility In Myrtle BeachAdma Biologics Advances Plasma Collection Center Expansion Plans With Opening Of New Facility In Myrtle Beach
cmlviz.com - November 16 at 1:48 PM
Eiger BioPharmaceuticals (NASDAQ:EIGR) & ADMA Biologics (NASDAQ:ADMA) Head to Head SurveyEiger BioPharmaceuticals (NASDAQ:EIGR) & ADMA Biologics (NASDAQ:ADMA) Head to Head Survey
americanbankingnews.com - November 16 at 11:38 AM
ADMA Biologics Inc. (NASDAQ: ADMA) Investors To Make Big Returns AgainADMA Biologics Inc. (NASDAQ: ADMA) Investors To Make Big Returns Again
marketingsentinel.com - November 16 at 8:47 AM
ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SCADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SC
finance.yahoo.com - November 16 at 8:47 AM
ADMA Biologics, Inc. (NASDAQ:ADMA) Forecasted to Post Q1 2022 Earnings of ($0.07) Per ShareADMA Biologics, Inc. (NASDAQ:ADMA) Forecasted to Post Q1 2022 Earnings of ($0.07) Per Share
americanbankingnews.com - November 15 at 3:02 AM
ADMA Biologics, Inc. (NASDAQ:ADMA) Expected to Post Quarterly Sales of $21.83 MillionADMA Biologics, Inc. (NASDAQ:ADMA) Expected to Post Quarterly Sales of $21.83 Million
americanbankingnews.com - November 13 at 4:56 AM
ADMA Biologics, Inc. Expected to Post FY2021 Earnings of ($0.47) Per Share (NASDAQ:ADMA)ADMA Biologics, Inc. Expected to Post FY2021 Earnings of ($0.47) Per Share (NASDAQ:ADMA)
americanbankingnews.com - November 13 at 3:02 AM
ADMA Biologics Inc. [ADMA] Is Currently 13.57 above its 200 Period Moving Avg: What Dose This Mean?ADMA Biologics Inc. [ADMA] Is Currently 13.57 above its 200 Period Moving Avg: What Dose This Mean?
dbtnews.com - November 12 at 7:48 AM
ADMA Biologics Inc. (NASDAQ:ADMA) Up Almost 39.47% In 1 Month, Long Term Looking Good As WellADMA Biologics Inc. (NASDAQ:ADMA) Up Almost 39.47% In 1 Month, Long Term Looking Good As Well
marketingsentinel.com - November 12 at 7:48 AM
ADMA Biologics Shares Rally 15% on Strong 3Q, Upgrade >ADMAADMA Biologics Shares Rally 15% on Strong 3Q, Upgrade >ADMA
marketwatch.com - November 11 at 3:41 PM
ADMA Biologics Shares Rise On Lower Than Expected Q3 Loss, Sales DoubleADMA Biologics Shares Rise On Lower Than Expected Q3 Loss, Sales Double
msn.com - November 11 at 9:44 AM
DateCompanyBrokerageAction
11/17/2021Aptose BiosciencesCantor Fitzgerald
Reiterated Rating
11/12/2021Aptose BiosciencesHC Wainwright
Boost Price Target
11/11/2021ADMA BiologicsRaymond James
Upgrade
11/8/2021ADMA BiologicsCantor Fitzgerald
Initiated Coverage
10/26/2021ADMA BiologicsRaymond James
Lower Price Target
10/12/2021Adverum BiotechnologiesSVB Leerink
Reiterated Rating
10/8/2021ADMA BiologicsMaxim Group
Initiated Coverage
9/20/2021ADMA BiologicsJefferies Financial Group
Initiated Coverage
8/12/2021ADMA BiologicsHC Wainwright
Lower Price Target
7/30/2021Adverum BiotechnologiesRoyal Bank of Canada
Reiterated Rating
7/26/2021ADMA BiologicsHC Wainwright
Reiterated Rating
7/23/2021Adverum BiotechnologiesThe Goldman Sachs Group
Downgrade
7/23/2021Adverum BiotechnologiesSVB Leerink
Lower Price Target
7/23/2021Adverum BiotechnologiesChardan Capital
Lower Price Target
7/23/2021Adverum BiotechnologiesCantor Fitzgerald
Downgrade
7/20/2021Elevation OncologyJPMorgan Chase & Co.
Initiated Coverage
7/20/2021Elevation OncologyWedbush
Initiated Coverage
7/20/2021Elevation OncologySVB Leerink
Initiated Coverage
7/20/2021Elevation OncologyCowen
Initiated Coverage
7/19/2021Miromatrix MedicalCraig Hallum
Initiated Coverage
7/6/2021ADMA BiologicsHC Wainwright
Lower Price Target
7/5/2021Aptose BiosciencesPiper Sandler
Lower Price Target
7/1/2021Adverum BiotechnologiesChardan Capital
Reiterated Rating
5/10/2021Adverum BiotechnologiesSVB Leerink
Reiterated Rating
5/5/2021Adverum BiotechnologiesRoyal Bank of Canada
Reiterated Rating
5/5/2021Adverum BiotechnologiesTruist Securities
Reiterated Rating
5/5/2021Adverum BiotechnologiesChardan Capital
Reiterated Rating
5/3/2021Adverum BiotechnologiesSVB Leerink
Downgrade
4/29/2021Adverum BiotechnologiesLifesci Capital
Downgrade
4/29/2021Adverum BiotechnologiesChardan Capital
Downgrade
4/29/2021Adverum BiotechnologiesTruist Securities
Downgrade
4/29/2021Adverum BiotechnologiesTruist
Downgrade
4/29/2021Adverum BiotechnologiesSVB Leerink
Lower Price Target
4/29/2021Adverum BiotechnologiesRoyal Bank of Canada
Downgrade
4/5/2021ADMA BiologicsJefferies Financial Group
Reiterated Rating
3/26/2021ADMA BiologicsMaxim Group
Reiterated Rating
3/26/2021ADMA BiologicsRaymond James
Lower Price Target
3/24/2021Aptose BiosciencesOppenheimer
Boost Price Target
3/2/2021Adverum BiotechnologiesCantor Fitzgerald
Reiterated Rating
2/22/2021Aptose BiosciencesJonestrading
Initiated Coverage
1/4/2021ADMA BiologicsHC Wainwright
Lower Price Target
12/15/2020Adverum BiotechnologiesUBS Group
Initiated Coverage
11/12/2020Adverum BiotechnologiesRaymond James
Upgrade
11/5/2020Adverum BiotechnologiesLifesci Capital
Reiterated Rating
10/20/2020Aptose BiosciencesCanaccord Genuity
Reiterated Rating
10/19/2020Aptose BiosciencesCantor Fitzgerald
Initiated Coverage
10/1/2020ADMA BiologicsRaymond James
Boost Price Target
9/22/2020Aptose BiosciencesAlliance Global Partners
Initiated Coverage
8/26/2020Adverum BiotechnologiesRaymond James
Reiterated Rating
8/11/2020Adverum BiotechnologiesSVB Leerink
Boost Price Target
8/10/2020Adverum BiotechnologiesPiper Sandler
Boost Price Target
8/6/2020ADMA BiologicsHC Wainwright
Reiterated Rating
8/6/2020ADMA BiologicsOppenheimer
Initiated Coverage
7/28/2020ADMA BiologicsHC Wainwright
Reiterated Rating
6/23/2020Aptose BiosciencesPiper Sandler
Reiterated Rating
6/14/2020Aptose BiosciencesOppenheimer
Initiated Coverage
6/12/2020Aptose BiosciencesMaxim Group
Initiated Coverage
6/12/2020Aptose BiosciencesHC Wainwright
Reiterated Rating
5/22/2020ADMA BiologicsMaxim Group
Initiated Coverage
5/22/2020ADMA BiologicsHC Wainwright
Reiterated Rating
5/7/2020ADMA BiologicsOppenheimer
Lower Price Target
4/27/2020Aptose BiosciencesHC Wainwright
Reiterated Rating
3/16/2020ADMA BiologicsHC Wainwright
Lower Price Target
3/4/2020Aptose BiosciencesCanaccord Genuity
Reiterated Rating
2/20/2020Aptose BiosciencesMaxim Group
Initiated Coverage
2/6/2020Aptose BiosciencesHC Wainwright
Boost Price Target
1/9/2020Aptose BiosciencesPiper Sandler
Initiated Coverage
1/8/2020ADMA BiologicsHC Wainwright
Reiterated Rating
11/20/2019ADMA BiologicsHC Wainwright
Reiterated Rating
10/21/2019ADMA BiologicsMaxim Group
Set Price Target
8/27/2019ADMA BiologicsMaxim Group
Reiterated Rating
8/12/2019ADMA BiologicsDawson James
Downgrade
8/7/2019Aptose BiosciencesHC Wainwright
Lower Price Target
5/23/2019Aptose BiosciencesRoth Capital
Reiterated Rating
4/2/2019Aptose BiosciencesHC Wainwright
Set Price Target
3/22/2019Aptose BiosciencesHC Wainwright
Set Price Target
3/1/2019Aptose BiosciencesRoyal Bank of Canada
Initiated Coverage
1/25/2019Aptose BiosciencesCitigroup
Initiated Coverage
1/24/2019Aptose BiosciencesOppenheimer
Initiated Coverage
12/13/2018Aptose BiosciencesHC Wainwright
Set Price Target
(Data available from 12/7/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.